The effectively of favipiravir as antiviral therapy in the treatment of covid-19 in the several hospital in Blora, Indonesia

Abstract

The outbreak of Corona virus Disease 2019 (COVID-19) in December 2019 in China, has become a pandemic in March 2020. A clinical study in China on the effectiveness of favipiravir involving 320 COVID-19 patients stated that favipiravir was safe and efficacious in the treatment of COVID-19. However, in Indonesia, the clinical studies on the effectiveness and the toxicity of the antiviral are so lacking that the further research will be needed. The objective of the study is to analize the effectiveness of favipiravir as an antiviral therapy in the treatment of COVID-19 in several hospital in the district of Blora, Central Java, Indonesia. In this study as many as 266 samples of the patient’s medical record which met the inclusion criteria were devided into group 1 which given favipiravir and group 2 which not given favipirafir. Data were then analized by using chi-square with continuity correction to evaluate the difference in proportion of those who were given the antiviral and those who were not, in relation to the outcome. The result showed that as many as 92.5% of the patient given favipiravir showed an improved outcome and 7.5% of those were reported dead. As many as 80.5% of those not given favipiravir showed an improved outcome and 19.5% of those were reported dead. Based on the chi square with continuity correction, it revealed that there was significant difference in the proportion among the groups in relation to the outcome (p<0,05). Based on the results and discussions, it is concluded that favipiravir is effective to be used as an antiviral drug in the treatment of COVID-19.